Loading...
•
Jul 04, 2021
Revvity Q2 2021 Earnings Report
PerkinElmer reported revenue growth of 51% and organic revenue growth of 41%. GAAP EPS from continuing operations was $2.19 and adjusted EPS was $2.83. The company initiated third quarter guidance and raised full-year revenue and earnings guidance. Also, the company announced agreement to acquire BioLegend.
Key Takeaways
PerkinElmer announced financial results for the second quarter of 2021, with a revenue of $1.228 billion, a 51% increase in reported growth and a 41% increase in organic growth. GAAP EPS from continuing operations was $2.19, and adjusted EPS was $2.83. The company has initiated third quarter guidance and raised full-year revenue and earnings guidance. Additionally, they announced an agreement to acquire BioLegend.
Revenue of $1.228 billion; 51% reported growth; 41% organic growth
GAAP EPS from continuing operations of $2.19
Adjusted EPS of $2.83
Announced Agreement to Acquire BioLegend
Forward Guidance
For the third quarter of 2021, the Company forecasts adjusted revenue of approximately $1.00 billion and adjusted earnings per share of $1.62. For the full year of 2021, the Company now forecasts adjusted revenue of $4.57 billion and adjusted earnings per share of $9.88.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...